Alvotech Chases Debt Backup As Shareholders Redeem From The Pot
Newly Public Company Has $128m In Available Cash
Alvotech is furthering efforts to have a debt facility in place worth up to $125m as it kicks off life as a public company, amid challenging global market conditions.
You may also be interested in...
Alvotech Acquires Reykjavik Manufacturing Facility Amid $136m Financing Boost
Months after it become a public company, Alvotech has once again turned to the debt/equity markets to provide financial firepower for its pipeline of biosimilar candidates.
Stada And Alvotech Launch Higher-Strength Adalimumab In Europe
Stada and Alvotech have announced the launch of the Hukyndra higher-strength adalimumab biosimilar rival to Humira in selected European countries, with a wider roll-out to follow in the coming months.
Alvotech’s Ustekinumab Passes Safety And Efficacy Milestone
Alvotech has announced success in its confirmatory clinical safety and efficacy study for its AVT04 ustekinumab candidate, a proposed biosimilar to Stelara.